Agilent news in 2026: 22 dated events
The latest Agilent event on this page is dated Sep 4, 2026. ad-hoc-news.de reported: Agilent Technologies stock gains on digital pathology launch and strong Q3 figures.
Public (A)Biotechnology Research10,000+ employeesagilent.comLinkedIn
- Dated events
- 29
- Last 90 days
- 8
- Latest
- Sep 4, 2026
News · latest 10
Latest Agilent news
Showing 10 of 29 dated events. The Signal API returns all of them.
Get them with one API call- Agilent Technologies stock gains on digital pathology launch and strong Q3 figuresAgilent Technologies launched its Agilent S540MD Slide Scanner System in the U.S. after receiving FDA clearance.
- Agilent launches new ICP-MS, GC Systems and Digital Lab Execution platform in IndiaAgilent Technologies has launched three new laboratory solutions in India: the Agilent 9500 Triple Quadrupole ICP-MS, new 8890B and 8860B Gas Chromatography Systems, and the OpenLab Sync Lab Execution System.
- Agilent reports Q3 fiscal 2026 revenue $1.88B, raises FY26 guidance, non-GAAP EPS $1.62Agilent Technologies reported third-quarter fiscal 2026 revenue of $1.88 billion, an 8.1% increase year-over-year.
- Earnings To Watch: Agilent (A) Reports Q2 Results TomorrowAgilent Technologies reported revenues of $1.84 billion in its previous quarter, a 10% increase year-on-year.
- Agilent Technologies stock touches fresh 52-week high as investors position ahead of Q3 earningsAgilent Technologies' Applied Markets segment is expected to report net revenue of $336.29 million in the upcoming quarter, a 3.8% year-over-year increase.
- Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CarcinomaAgilent Technologies Inc. has received European Union (EU) certification for its PD-L1 IHC 22C3 pharmDx, a companion diagnostic to identify patients with certain types of carcinoma who may be eligible for treatment with Merck's KEYTRUDA.
- Agilent Technologies (NYSE:A) Gains Fresh FDA MomentumAgilent Technologies has secured regulatory clearance from the FDA for its PD-L1 IHC pharmDx assay, a precision oncology companion diagnostic for several gastrointestinal cancers.
- Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal AdenocarcinomaAgilent Technologies received FDA approval for its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic for certain types of esophageal and gastric cancers.
Showing 10 of 29 dated events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Agilent with the Signal API
One POST /v1/companies/enrich call with agilent.com returns Agilent news signals (news), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"agilent.com","signal_types":["news"],"limit":20}'Same industry
News at related companies
Questions about Agilent news
What is the latest news on Agilent?
What is going on with Agilent?
Source. News articles about the company, one source link per event.
Method. Stories about the same event within 14 days merge into one row. Noise (lists, stock tips, recaps) is removed.
Data as of .